Publications by authors named "Tatsuhiko Kamoshida"
Article Synopsis
- The study investigates the effectiveness of durvalumab combined with chemoradiotherapy (CRT) versus CRT alone in treating locoregional recurrence of non-small-cell lung cancer (NSCLC) after complete resection.
- Using propensity score analysis to adjust for confounding variables, the research involved 119 patients in the CRT-D group and 111 in the CRT group, noting differences in gender distribution and adenocarcinoma rates.
- Results indicated that the median progression-free survival was significantly longer in the CRT-D group (25.4 months) compared to the CRT group (11.5 months), suggesting that the combination treatment could be a beneficial strategy for these patients.
An 85-year-old woman was diagnosed with coronavirus disease 2019 (COVID-19). The patient was treated with dexamethasone, and the infection was cured. She later developed a low-grade fever and fell unconscious.
View Article and Find Full Text PDFBackground: Immune checkpoint inhibitor (ICI) has become the standard therapy for metastatic non-small cell lung cancer (NSCLC) patients. However, no robust evidence on the efficacy and safety of ICI in elderly NSCLC patients has been established.
Materials And Methods: This retrospective study aimed to assess the efficacy and safety of ICI in elderly NSCLC patients.